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Although leiomyosarcomas (LMSs) form the largest subgroup of soft tissue sarcomas (STSs), the eﬃcacy of chemotherapy in
this group is largely unclear, partly because older studies are contaminated with gastrointestinal stromal tumors (GISTs). In this
retrospective study we investigated the outcome of ﬁrst line chemotherapy in 65 patients with unresectable or metastatic LMS. The
overall response rate (ORR) was 18%; and the median progression-free (PFS) and overall survival (OS) were 3.8 and 9.7 months
respectively. No statistically signiﬁcant diﬀerences in outcomes for uterine and non-uterine LMS were found. In non-uterine LMS,
however, the PFS and OS seemed to be longer for females than for males, potentially negatively aﬀecting outcomes in this group. If
our observations are conﬁrmed in other series, they would suggest that studies performed in STS patients should not only stratify
for histological subtype but also for uterine versus non-uterine LMS and for gender.
Copyright © 2009 A. W. Oosten et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
A d u l ts o f tt i s s u es a r c o m a s( S T S s )a r eah e t e r o g e n e o u sa n d
rare group of tumors accounting for only 1% of all cancers.
This group comprises over 50 diﬀerent tumor entities with
considerable diﬀerences in terms of clinical behaviour and
genetic variances. Despite improvements in treatment over
the past years, many patients present with locally advanced
or metastatic disease and are therefore not amenable to
surgical therapy. For these patients palliative chemotherapy
is an option. With the exception of gastrointestinal stromal
tumors (GISTs) and small blue round cell sarcomas such
as Ewing-like tumors and rhabdomyosarcomas, systemic
chemotherapy for the diﬀerent STS subtypes is largely
similar, with doxorubicin (DOX) and ifosfamide (IFS)
being the backbone of treatment [1, 2]. In recent years,
however, the insight has emerged that systemic therapy
shouldbecomemoretailored,forSTSinparticularaccording
to the histological subtype. The correctness of this approach
is clearly illustrated by the remarkable eﬃcacy of imatinib
in patients with advanced GISTs and dermatoﬁbrosarcoma
protuberans, while other subtypes of STS do not respond
to imatinib at all [3–5]. Other examples include the activity
of taxanes in patients with metastatic angiosarcoma, in
particular those originating in the head and neck region
[6–8] and of trabectidin in patients with myxoid/round cell
liposarcomas [9].
A large subgroup of STSs accounting for approximately
24% of all STSs is the group of leiomyosarcomas (LMSs)
[10]. LMS is a mesenchymal tumor of smooth muscle origin
found in the uterus, gastrointestinal tract, or deep soft
tissue. Cutaneous LMS is a site-speciﬁc subtype of LMS2 Sarcoma
with a very good prognosis. Outcomes obtained by systemic
therapy for LMS are rather poor compared to the eﬃcacy in
other STS subtypes [11, 12]. However, since GIST resembles
LMS histopathologically and only recently can be reliably
distinguished from LMS, many GISTs have been diagnosed
as LMSs in older series. As it is known at the moment that
GISTs are almost completely resistant to standard cytotoxic
chemotherapy [13], the eﬃcacy of chemotherapy in pure
LMS, therefore, requires further investigation. Additionally,
within the group of noncutaneous LMS, two main categories
can be distinguished: tumors arising from the uterus versus
non-uterineLMS.Arecentstudyreporteddiﬀerencesingene
expression patterns between uterine and non-uterine LMS
[14]. Moreover, in contrast to other STS entities, uterine
LMSs seem to be in particular sensitive to the combination
of gemcitabine and docetaxel [15].
Consequently, more insight into the outcome of chem-
otherapy in LMS as well as further research into possi-
ble diﬀerences between uterine and non-uterine LMS is
needed. This retrospective analysis aimed to describe the
activity and outcome of chemotherapy in patients with
advanced/metastatic LMS and to assess whether there are
diﬀerences between LMS originating in the uterus versus
LMS originating elsewhere.
2. Patientsand Methods
From the institutional database of the Erasmus MC-Daniel
denHoed,atertiarycancercentreinRotterdam,TheNether-
lands, we selected patients with leiomyosarcoma who were
treated with ﬁrst-line chemotherapy for locally advanced
or metastatic disease. Patients who received only adjuvant
chemotherapy were not included in the analysis. Followup
data were available until the 1st of December 2007.
Clinical and demographical data were collected by
reviewing patient ﬁles. Recorded baseline characteristics
included sex, age at diagnosis, site of primary LMS, his-
tological subtype (if available), sites of metastases, and
WHO performance status at the start of chemotherapy.
Furthermore, data were recorded on type of response and
PFS (see below). Survival data were collected from the charts
and, if missing, by contacting the general practitioner or by
checking the municipal registries.
For all patients, histological examination was performed
at our hospital by specialised soft tissue pathologists either
after primary surgery or upon revision after referral. For the
purpose of this analysis, revision of histological material was
repeated in those patients in whom GIST was suspected on
clinical grounds. Soft tissue leiomyosarcomas were graded
using the FNCLCC (F´ ed´ eration Nationale de Centres de
LutteContreleCancer)system.Grade1tumorsweredeﬁned
as low grade, grades 2 and 3 tumors as high grade. Uterine
leiomyosarcomas were deﬁned as either high or low grade
according to mitotic activity and necrosis.
All radiological examinations were performed at our
hospital. Patients underwent a baseline CT scan before
starting chemotherapy, and evaluation CT-scanning was
performed after each 2 or 3 cycles of chemotherapy in
most patients. Response was evaluated according to the
WHO criteria in those patients treated before 2000 and
according to the Response Evaluation Criteria In Solid
Tumours (RECIST) criteria [16] for those patients treated
beyond2000.OutcomesareknowntobesimilarinSTSswith
either criteria [17].
PFS was deﬁned as the time (months) between start of
chemotherapy until disease progression or death, whatever
came ﬁrst. OS was deﬁned as the time (months) between
start of chemotherapy until death from any cause.
Patients who were treated with the goal of making
locally advanced disease amendable for surgical resection
(induction chemotherapy) were excluded from analysis of
progression free and overall survival but were included for
analysis of response rates.
3.StatisticalAnalyses
Response rates, median progression free survival (PFS), and
overall survival (OS) from the start of chemotherapy are
reported for the whole group of STS and were compared
between uterine LMS and LMS originating elsewhere. Per-
centages were compared with chi-square tests. Analysis of
PFS and OS was performed with Kaplan-Meier curves and
the log rank test.
4. Results
Sixty-nine patients with LMS who received chemotherapy
between January1991 and August2007 wereidentiﬁed. After
exclusion of two patients who were treated with adjuvant
chemotherapy and two patients who were found to have
a GIST on revision, 65 patients with locally advanced or
metastatic disease remained eligible and were included in the
analysis.
At the time of analysis, 56 patients had died; 7 patients
remainedalive.For2patientsitwasreasonabletobelievethat
they had died, but this could not be conﬁrmed (no data were
available in the municipal registry, and it was assumed that
both patients died abroad).
Patient characteristics of the two groups, non-uterine
(n = 32)anduterineLMS(n = 33) , respectively, are given in
Table 1. Except for the obvious gender diﬀerence, there were
no signiﬁcant diﬀerences between both groups.
Fifty-ﬁve patients had distant metastases, of whom 16
patients also had a relapse at the primary site, and 10
patients had locally advanced disease without signs of distant
metastases. Of the latter patients, 9 received chemotherapy
with the aim to decrease tumor size potentially allowing a
subsequent resection (induction treatment), while for one
patient the intention of treatment was palliation because the
clinical condition was considered too poor (WHO PS 2) to
undergo subsequent surgery.
Treatment characteristics are described in Table 2.
Because in our hospital, STS patients are preferentially
treated in the context of studies conducted by the European
Organisation of Research and Treatment of Cancer-Soft
Tissue and Bone Sarcoma Group (EORTC-STBSG), a wideSarcoma 3
Table 1: Patient characteristics, n = 65.
Non-Uterine LMS % Uterine LMS %
(n = 32) (n = 33)
Gender
Male 13 41
Female 19 59 33 100
Median age at diagnosis 55.5 yrs 54.4 yrs
Range 30–74 33–74
Histology
Spindle cell 6 19 3 9
Epitheloid 0 2 6
Pleiomorph 7 22 6 18
Unknown 19 59 22 67
Primary disease localisation
Extremity 17 53 —
Non-extremity 15 47 —
Locally advanced disease
Without distant metastases 5 16 4 12
With distant metastases 6 19 12 36
Distant Metastases (M1)
One site, no liver 10 37 15 52
One site, liver 2 7 0 0
≥2s i t e s ,n ol i v e r 8 3 0 9 3 1
≥2 sites, including liver 7 26 5 17
WHO PS before start chemotherapy
01 0 3 1 9 2 7
12 1 6 6 2 3 7 0
21 3 1 3
Table 2: Treatment characteristics.
Non-Uterine % Uterine %
(n = 32) (n = 33)
Chemotherapy
Yes 32 33
Induction chemotherapy (for locally advanced disease) 5 4
No 27 29
Chemotherapeutic regimen
Monotherapy
Doxorubicine 75mg/m2,q3w k 1 7 5 3 2 0 6 1
Ifosfamide 9gr/m2,q3w k 8 2 5 7 2 1
Ifosfamide 5gr/m2 in 24 hrs, q 3 wk 1 0
Epirubicine 150mg/m2,q3w k 1 1
Docetaxel 100mg/m2,q3w k 1 1
Combination
Doxorubicine 75 mg/m2 +i f o s f a m i d e9g r / m 2,q3w k 0 1
Doxorubicine 75mg/m2 + ifosfamide 10gr/m2 (4 × 2.5), q 3 wk 2 1
Doxorubicine 75mg/m2 +i f o s f a m i d e5g r / m 2,q3w k 0 1
Doxorubicine 50mg/m2 +i f o s f a m i d e5g r / m 2 dg 1, q 3 wk 1 1
Doxorubicine 60mg/m2 +i f o s f a m i d e5g r / m 2,q3w k 1 0
Median number of cycles 4 (1–7) 4 (1–7)4 Sarcoma
Table 3: Response rate of ﬁrst line chemotherapy.
Best response Non-Uterine % Uterine %
(WHO/RECIST) (n = 32) (n = 33)
CR 0 1 3
PR 7 22 4 12
SD 15 47 14 42
PD 9 28 14 42
Non-evaluable 1 3 0 0
CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease.
0
0.25
0.5
0.75
1
0 1 22 43 64 8
(months)
Male
Female uterine
Female non-uterine
Figure 1: Progression free survival according to gender and site of
origin.
variety of chemotherapeutic regimens were used over the
years. There were no signiﬁcant diﬀerences in administered
chemotherapeutic regimens between the patients with uter-
ine versus non-uterine LMS.
Overall, the RR (RR, = complete (CR) + partial response
(PR)) was 18% in the patients evaluable for response (n =
64 , see Table 3), while for the 56 patients evaluable for
survival, the median PFS and OS were 3.8 months and 9.7
months, respectively. Dissecting non-uterine from uterine
LMS, the overall response rates (CR + PR) were 22% and
15%, respectively (Table 3)( P = .2 6 ) .M e d i a nP F Sa n dO S
in non-uterine LMS was 5.1 and 11.6 months, respectively,
compared to 3.7 months and 8.3 months, respectively,
in uterine LMS, which was not statistically signiﬁcantly
diﬀerent (P = .76 for PFS and P = .74 for OS) (Figures
1 and 2). After correction for prognostic factors for the
whole group (age at the start of chemotherapy, tumor size,
histological subtype, and absence or presence of distant
metastases and their localisation), no statistically signiﬁcant
diﬀerences were found.
Regarding the 27 patients with a non-uterine LMS, the
PFS and OS in men (n = 12) were 2.7 months and 7.9
months, respectively, while these measures in women were
longerbeing6.0monthsand18.9months,respectively.These
diﬀerences, however, again were not statistically signiﬁcant
(P = .48 for PFS, P = .47 for OS).
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Figure 2: Overall survival according to gender and site of origin.
5. Discussion
In this retrospective analysis on the outcome of ﬁrst-line
chemotherapy in patients with advanced or metastatic LMS,
we found an overall response rate (ORR) of 18% (CR + PR).
Median PFS and OS were 3.8 and 9.7 months, respectively.
The ORR was not signiﬁcantly diﬀerent in non-uterine
versus uterine LMS, while there was a trend for longer
PFS and OS in female patients with a non-uterine LMS as
compared to men.
Although LMSs form one of the largest subgroups of
soft tissue sarcomas [10], little is known about the eﬃcacy
of chemotherapy for this entity. Although previous STS
studies have speciﬁed outcomes for LMS, it is likely that
these studies were contaminated with GIST patients. It is
only since the recent advent of immunohistochemistry, and
if necessary molecular characterisation, that GIST can be
reliably distinguished from LMS.
Regarding the outcome measures ORR, PFS, and OS,
previous studies have shown comparable although slightly
better outcomes for LMS than in our current analysis. The
largest study, a retrospective analysis of 2185 patients (1922
assessable for response) with advanced STS treated in studies
of the EORTC-STBSG, showed an overall response rate of
26% for the total group of STSs, compared to 22% for
492 patients with LMS. Median OS was 51 weeks for the
whole group and 52 weeks for patients with LMS [12].Sarcoma 5
Another study of this group, largely containing similar cases
as the former study, revealed that in terms of progression-
free rates at 3 and 6 months after initiation of ﬁrst-line
therapy, LMS patients in general did worse than patients
with other STS entities [18]. A third study, a retrospective
analysisof488STSpatientsmostlytreatedwithdoxorubicine
and/or ifosfamide, showed a median OS of 11 months for
the LMS patients, while OS for patients with other common
STS entities including synovial sarcomas, liposarcomas, and
ﬁbrosarcomas was better being 19, 18, and 14 months,
respectively [19]. In all of these studies it is likely that cases
of GIST were included in the LMS groups. With this caveat
in mind, these studies suggest that outcomes in LMS patients
are at the lowest boundary of antitumor activity achieved by
ﬁrst-line chemotherapy in STS.
With respect to the subgroup of LMSs, there are
several indications that LMS arising in the uterus is bio-
logically diﬀerent than LMS originating elsewhere. Firstly,
gene expression proﬁling studies suggest a small diﬀerence
between uterine and other LMSs. Although the majority of
expressed gene fragments are similar, about 25 discriminator
genes diﬀerentiate between the two groups. These genes are
primarily related to tissue type [14, 20]. Secondly, several
studies suggest that uterine LMS diﬀers with respect to
sensitivity to chemotherapy compared to other STS types.
While gemcitabine is considered inactive in unselected STS
[21,22],severalphaseIIstudieshaveshownthatgemcitabine
monotherapycanproduceantitumoractivityinuterineLMS
[23–27]. Furthermore, in two phase II trials the combination
ofgemcitabineanddocetaxel,thelatteralsoregardedinactive
inunselectedSTS[28],wasrecentlyfoundtoinduceremark-
ably high response rates of 35% to 53% in patients with
advanced uterine LMS [15, 29]. Median PFS and OS were
4.4 months and 16 months, respectively, in the most recent
Study of the Gynecologic Oncology Group. Also, Bay et al.
retrospectively evaluated the combination of gemcitabine
and docetaxel in 133 patients with STS, including 76 LMSs
[30]. They found an overall response rate of 18.4%, being
24.2% for LMS and 10.4% for other STSs, respectively (P =
.06). The median overall survival of the total group was 12.1
months, but overall survival was better for LMS patients
versus patients with other histologies (P = .01). Response
ratesandsurvivalwerethesameforuterineLMSversusother
primary sites of LMS. Overall, although nonrandomised
and retrospective studies are highly prone for selection bias,
which may aﬀect outcomes, most of the performed studies
point at a diﬀerence between uterine and non-uterine LMSs.
As a result, uterine LMS should be distinguished from non-
uterine LMS for future studies. In our study population, in
which no gemcitabine/docetaxel-containing chemotherapy
was given, there were no statistically signiﬁcant diﬀerences
between non-uterine and uterine LMSs in terms of response
rates according to WHO and RECIST, OS, and PFS. It
would be worthwhile to further investigate the value of
gemcitabine/docetaxel in uterine LMSs in greater groups.
Remarkably, in our analysis survival times seemed longer
for females with non-uterine LMS, compared to male LMS
patients (OS 18.9 versus 7.9 months, PFS 6.0 versus 2.7
months). It should be noted that these diﬀerences were not
statistically signiﬁcant which, however, may be due to the
small numbers. This seemingly worse outcome for males
with LMS, which adversely aﬀects the outcomes of the whole
group with non-uterine LMS, is in line with studies in tumor
types other than STS also reporting worse outcomes for
males. It is postulated that this may be due to diﬀerences in
body mass index and composition and diﬀerences in drug
pharmacodynamics and drug metabolism [31].
In conclusion, this study provides data on the outcome
of chemotherapy for LMS patients. Although no signiﬁcant
diﬀerences were found for primary uterine versus non-
uterine disease localisation, worse outcomes in male LMS
patients may negatively aﬀect outcomes in the non-uterine
group. If our observations are conﬁrmed in other series, they
would suggest that studies performed in STS patients should
not only be stratiﬁed for LMS but also for uterine and non-
uterine primary disease localisation and for gender.
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